Zentralinstitut für Seelische Gesundheit (ZI) Mannheim
Mannheim, Deutschland
Behandlung & Zugang
- Angebotene Behandlungenpsilocybin
- ZugangswegHärtefallprogramm (Compassionate Use)
- Kosten & Übernahme (Registerstatus)No price published for Compassionate Use treatment; psilocybin (PEX010) supplied within the authorised Expanded Access Programme; treatment inpatient-only at a public-mandate institution
- Telefon+49 621 1703-0 (switchboard); +49 621 1703-2850 (Zentralambulanz, info & appointments 08:30-16:00)
- Websitehttps://zi-mannheim.de
Über diesen Anbieter
The Zentralinstitut fuer Seelische Gesundheit (Central Institute of Mental Health, CIMH) in Mannheim is one of Germany's leading psychiatric research and care institutions. Since 11 July 2025 it runs - together with the OVID day clinic in Berlin and under the direction of Prof. Dr. Gerhard Gruender (Dept. of Molecular Neuroimaging) - the first Compassionate Use / Expanded Access Programme for psilocybin in the European Union, for adults with treatment-resistant depression in justified exceptional cases. Treatment is inpatient-only: single doses of psilocybin (usually 25 mg, PEX010 by Filament Health) embedded in psychotherapeutic preparation and follow-up. CIMH led the EPIsoDE study (2021-2024, with Charite and the MIND Foundation), Germany's largest psilocybin TRD trial, and currently recruits for LSD (MM120) and deuterated-psilocin (CYB003) trials.
Leistungen & Programme
- Psilocybin treatment for treatment-resistant depression within Compassionate Use / Expanded Access Programme (inpatient; single doses usually 25 mg + accompanying psychotherapy; outpatient appointments for eligibility check, preparation and follow-up)
- Participation in psychedelic clinical trials (see programs)
- General psychiatric care via Department of Psychiatry and Psychotherapy; Zentralambulanz (central outpatient intake); 24/7 psychiatric emergency service (+49 621 1703-7777)
Programme & Studien
| Programm | Art | Status |
|---|---|---|
| Expanded Access Programme (Compassionate Use) for psilocybin in treatment-resistant depression - first for this substance in the EU; sites: CIMH Mannheim and OVID day clinic Berlin; director Prof. Dr. Gerhard Gruender; drug PEX010 (botanical psilocybin) by Filament Health; approved by BfArM | active since 11 July 2025; exceptional cases only; substantial waiting list | |
| MM120 (LSD-D-tartrate) for generalized anxiety disorder | recruitment started | |
| CYB003 (deuterated psilocin) for major depressive disorder | recruitment started | |
| EPIsoDE study - psilocybin 25 mg + psychotherapy for treatment-resistant unipolar depression (Jun 2021 - Dec 2024; CIMH lead, with Charite Berlin and MIND Foundation); ~30% response at 12 weeks; main results under journal review | completed |
Preise
| Leistung | Preis |
|---|---|
| Compassionate Use psilocybin treatment | no price published on site |
Ausstattung & Sprachen
- Ausstattung
- Campus at J 5, 68159 Mannheim
- Dedicated therapy rooms for psychedelic substance sessions (pictured on site)
- Inpatient wards (CU treatment exclusively inpatient)
- 24/7 emergency service
- SprachenGerman; full English website mirror
- TeamProgramme director: Prof. Dr. Gerhard Gruender, Head of the Department of Molecular Neuroimaging at CIMH (submitted the successful BfArM application). Treatment team draws on experience from clinical psilocybin/psychedelics studies; in the EPIsoDE protocol participants were accompanied by two therapists during substance sessions.
Häufige Fragen
Who can be treated with psilocybin at ZI?
Individual adult patients with treatment-resistant depression, in justified exceptional cases only: serious illness, no satisfactory treatment with approved drugs, and no possibility of joining a clinical trial; each case gets a benefit-risk assessment.
How do I apply?
Contact psychedelika-studien@zi-mannheim.de (or the web form) with full contact details and consent to data storage; you are then placed on the waiting list.
How long is the wait?
The institute states it receives very many inquiries and that considerable waiting times can occur; demand is expected to significantly exceed capacity.
Is the treatment outpatient?
No - psilocybin treatment within the CU programme takes place exclusively on an inpatient basis, with additional outpatient appointments for eligibility, preparation and follow-up.
Can I get psilocybin outside the programme or trials?
No - classic psychedelics in Germany are only permitted within officially approved clinical trials or the Expanded Access Programme; they remain controlled under the BtMG otherwise.
Verifizierung
- Lizenz / RegisterÖffentliches Studienregister (ClinicalTrials.gov / EU CTIS)
- Quellehttps://zi-mannheim.de
- Zuletzt verifiziert